J Cancer 2018; 9(23):4346-4354. doi:10.7150/jca.27251 This issue

Research Paper

Prognostic Value of the Cycle Number of Perioperative Chemotherapy in Locoregionally Advanced Rectal Cancer: a Propensity Score Matching Analysis

Hui Chang1,2*, Xin Yu1,2*, Kai Chen1,2, Qiao-xuan Wang1,2, Shu Zhang1,2, Zhi-fan Zeng1,2, Pei-rong Ding2,3, Zhi-zhong Pan2,3, Wei-wei Xiao1,2✉, Yuan-hong Gao1,2✉

1. Department of Radiation Oncology, Sun Yat-sen University Cancer Center.
2. State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine.
3. Department of Colorectal Surgery, Sun Yat-sen University Cancer Center.
*Hui Chang and Xin Yu contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Chang H, Yu X, Chen K, Wang Qx, Zhang S, Zeng Zf, Ding Pr, Pan Zz, Xiao Ww, Gao Yh. Prognostic Value of the Cycle Number of Perioperative Chemotherapy in Locoregionally Advanced Rectal Cancer: a Propensity Score Matching Analysis. J Cancer 2018; 9(23):4346-4354. doi:10.7150/jca.27251. Available from https://www.jcancer.org/v09p4346.htm

File import instruction


Background: Appropriate cycle number of perioperative chemotherapy for patients with locoregionally advanced rectal cancer (LARC) remains unknown. This study aimed to evaluate how cycle number of perioperative chemotherapy influenced the prognosis of LARC patients.

Methodology / Principal Findings: In this study, a total of 388 consecutive patients were enrolled and retrospectively reviewed if they were diagnosed with untreated stage cII-III LARC and treated with neoadjuvant chemoradiotherapy plus radical surgery followed by adjuvant chemotherapy or not. After grouping by the postoperative pathologic stage (yp0-I vs. ypII-III), propensity score matching was performed in each group to balance baseline characteristics between the patients treated with chemotherapy cycle ≤ 7 and those treated with chemotherapy cycle ≥ 8. The chemotherapy cycle was analyzed for its association with the survivals of the matched patients in the 2 groups, respectively. And the incidence of treatment-related complications was also compared. Through analysis, chemotherapy cycle ≥ 8 appeared to predict better overall, disease-free and distant-metastasis-free survivals in the whole cohort of matched patients (P values were 0.003, 0.002 and 0.004, respectively) and the ypII-III group (P values were 0.006, 0.005 and 0.014, respectively). But in the yp0-I group, chemotherapy of 8 cycles or more brought no improvement of survivals but only more acute toxicities (83.5% vs. 57.0%, P < 0.001).

Conclusions / Significance: Chemotherapy cycle ≥ 8 was proven associated with improved prognosis of LARC patients, especially those with ypII-III disease. But prolonged chemotherapy should be performed with caution in patients with yp0-I stage.

Keywords: rectal neoplasms, cycle number, perioperative chemotherapy